Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIXT Bioxytran	$0.08 -2.2%	$0.10	$0.06 ▼ $0.23	$6.76M	1.78	191,237 shs	44,213 shs
GBIO Generation Bio	$6.25 -2.2%	$4.25	$3.00 ▼ $29.40	$42.09M	2.67	173,235 shs	155,793 shs
OKUR OnKure Therapeutics	$2.73 -0.4%	$2.40	$1.70 ▼ $20.00	$36.88M	0.4	113,539 shs	42,409 shs
RNTX Rein Therapeutics	$1.15 +4.5%	$1.42	$1.04 ▼ $4.40	$26.50M	1.31	50,629 shs	111,231 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIXT Bioxytran	-3.60%	+0.13%	-18.04%	-44.66%	-22.30%
GBIO Generation Bio	-3.62%	+57.78%	+57.27%	+62.51%	-76.07%
OKUR OnKure Therapeutics	-2.14%	+37.00%	+17.60%	+21.78%	+273,999,900.00%
RNTX Rein Therapeutics	-2.65%	-6.78%	-22.54%	-43.30%	+109,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIXT Bioxytran	1.2138 of 5 stars	0.0	5.0	0.0	0.0	2.5	1.7	0.0
GBIO Generation Bio	3.2725 of 5 stars	3.3	3.0	0.0	0.0	2.0	3.3	1.3
OKUR OnKure Therapeutics	3.4037 of 5 stars	3.6	0.0	0.0	0.0	2.7	3.3	1.3
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIXT Bioxytran	0.00	N/A	N/A	N/A
GBIO Generation Bio	2.67	Moderate Buy	$10.67	70.67% Upside
OKUR OnKure Therapeutics	3.14	Buy	$32.33	1,084.37% Upside
RNTX Rein Therapeutics	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest BIXT, GBIO, RNTX, and OKUR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	RNTX Rein Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/18/2025	GBIO Generation Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
8/13/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$7.00 ➝ $7.00
8/13/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
8/13/2025	OKUR OnKure Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/18/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00 ➝ $70.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIXT Bioxytran	N/A	N/A	N/A	N/A	($0.03) per share	N/A
GBIO Generation Bio	$21.23M	1.98	N/A	N/A	$8.03 per share	0.78
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$5.79 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.46 per share	2.52	$0.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIXT Bioxytran	-$2.37M	-$0.03	N/A	∞	N/A	N/A	N/A	-1,577.96%	N/A
GBIO Generation Bio	-$131.67M	-$10.82	N/A	N/A	N/A	-341.12%	-91.07%	-33.65%	11/5/2025 (Estimated)
OKUR OnKure Therapeutics	-$52.67M	-$4.80	N/A	N/A	N/A	N/A	-60.52%	-55.43%	11/6/2025 (Estimated)
RNTX Rein Therapeutics	-$62.88M	-$2.69	N/A	N/A	N/A	N/A	-141.11%	-33.83%	N/A

Latest BIXT, GBIO, RNTX, and OKUR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RNTX Rein Therapeutics	-$0.22	-$0.28	-$0.06	-$0.28	N/A	N/A
8/12/2025	Q2 2025	GBIO Generation Bio	-$2.80	-$3.12	-$0.32	-$3.12	$2.51 million	$0.77 million
8/12/2025	Q2 2025	OKUR OnKure Therapeutics	-$1.23	-$1.14	+$0.09	-$1.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIXT Bioxytran	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIXT Bioxytran	N/A	N/A	N/A
GBIO Generation Bio	N/A	7.51	7.51
OKUR OnKure Therapeutics	N/A	11.13	11.13
RNTX Rein Therapeutics	N/A	0.86	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIXT Bioxytran	N/A
GBIO Generation Bio	95.22%
OKUR OnKure Therapeutics	90.98%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
BIXT Bioxytran	70.00%
GBIO Generation Bio	21.10%
OKUR OnKure Therapeutics	17.90%
RNTX Rein Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIXT Bioxytran	2	88.99 million	26.70 million	Not Optionable
GBIO Generation Bio	150	6.74 million	5.31 million	Optionable
OKUR OnKure Therapeutics	N/A	13.51 million	11.09 million	N/A
RNTX Rein Therapeutics	9	23.05 million	21.87 million	N/A

BIXT, GBIO, RNTX, and OKUR Headlines

Recent News About These Companies

Brookline Capital Downgrades Rein Therapeutics (RNTX)

August 19 at 11:47 PM | msn.com

Rein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trial

August 19 at 1:44 PM | msn.com

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

August 19 at 8:00 AM | globenewswire.com

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

August 14, 2025 | globenewswire.com

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

August 7, 2025 | finance.yahoo.com

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

July 30, 2025 | finance.yahoo.com

RNTX - Rein Therapeutics Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

June 24, 2025 | prnewswire.com

US FDA puts on hold Rein Therapeutics' lung disease drug trial

June 12, 2025 | reuters.com

RNTX Rein Therapeutics Inc.

June 1, 2025 | seekingalpha.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | finanznachrichten.de

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | prnewswire.com

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | prnewswire.com

Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment

May 13, 2025 | msn.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | finanznachrichten.de

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | prnewswire.com

Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment

May 2, 2025 | msn.com

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIXT, GBIO, RNTX, and OKUR Company Descriptions

Bioxytran OTCMKTS:BIXT

$0.08 0.00 (-2.19%)

As of 03:58 PM Eastern

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

Generation Bio NASDAQ:GBIO

$6.25 -0.14 (-2.19%)

Closing price 04:00 PM Eastern

Extended Trading

$6.34 +0.09 (+1.52%)

As of 04:11 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

OnKure Therapeutics NASDAQ:OKUR

$2.73 -0.01 (-0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$2.73 0.00 (0.00%)

As of 04:10 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Rein Therapeutics NASDAQ:RNTX

$1.15 +0.05 (+4.55%)

As of 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time